SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) Spike S1 (N501Y) Recombinant Protein His-Avi Lyophilized

SARS-CoV-2 (COVID-19) UK variant (B.1.1.7) Spike S1 (N501Y) Recombinant Protein His-Avi Lyophilized from Innovative Research has been recombinantly produced in HEK293 cells. This is a Lyophilized protein buffered in 20mM PB (pH 7.4). 5 % trehalose is added as protectant before lyophilization. with a purity of > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC

Endotoxin level is less than 1EU per ug by the LAL method..

More Details:

• Species: SARS-CoV-2
• Target:
• Purity: > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC
  
  Endotoxin level is less than 1EU per ug by the LAL method.
• Source: HEK293 cells
• Storage Conditions: Store in working aliquots at -20°C. Avoid freeze/thaw cycles.

Additional Information:

A new variant of SARS-CoV-2 is spreading in the UK and is rapidly becoming a global threat. It is characterized by multiple mutations in the spike protein. Among them, N501Y is of major concern because it involves one of the six key amino acid residues determining a tight interaction of the SARS-CoV-2 receptor-binding domain (RBD) with its cellular receptor angiotensin-converting enzyme 2 (ACE2).

SDS-PAGE. At Innovative Research we provide reliable, consistent products that deliver reliable, consistent results.

View all citations and product references

This material is sold for in-vitro use only for research. This material is not suitable for human or animal use. While we make every effort to ensure the safety of our products, we recommend handling any biological materials with standard precautions as if capable of spreading infectious disease. The statements herein are offered for informational purposes only to be used solely for your consideration, investigation, and verification.

Please be aware the image pictured is for illustrative purposes only, and your product packaging and appearance may vary.

No Data Sheets available